FDA Approves Investigational Device Exemption for RadioGel® Precision Radionuclide Therapy™ for Cancer

Vivos Inc. has received U.S. FDA approval for its Feasibility Investigational Device Exemption (IDE) application, allowing the company to initiate the first-in-human clinical feasibility study for RadioGel® Precision Radionuclide Therapy™. This innovative yttrium-90-based injectable hydrogel aims for targeted treatment of cancerous tumors, with the initial study focusing on non-resectable papillary thyroid carcinoma at Mayo Clinic.

Context

RadioGel® Precision Radionuclide Therapy™ utilizes yttrium-90, a radioactive isotope, combined with a hydrogel to deliver localized radiation directly to tumors. The FDA's IDE approval allows Vivos Inc. to conduct its first clinical feasibility study, which is crucial for assessing the safety and effectiveness of this innovative treatment. The study will focus on patients with non-resectable papillary thyroid carcinoma, a condition that currently has limited treatment options.

Why it matters

The FDA's approval of the Investigational Device Exemption is a significant step for Vivos Inc. and its RadioGel® therapy, which represents a new approach to cancer treatment. This therapy could potentially offer targeted treatment options for patients with specific types of tumors. Successful outcomes from the clinical study may pave the way for broader applications in oncology.

Implications

If the clinical study demonstrates that RadioGel® is effective, it could change treatment protocols for patients with non-resectable tumors. This therapy may also influence future cancer treatment strategies, particularly for hard-to-treat cancers. Patients and healthcare providers may gain access to new options that could improve outcomes and quality of life.

What to watch

The clinical feasibility study at Mayo Clinic will begin soon, and initial results will be closely monitored for safety and efficacy. Researchers will evaluate patient responses and any side effects associated with the treatment. Positive findings could lead to further studies and potential regulatory submissions for broader use.